📌 Key Takeaways
- JOURNAVX (suzetrigine) received FDA approval in January 2025 —
the first new-mechanism oral analgesic for moderate-to-severe acute pain in roughly 25 years. - It selectively blocks NaV1.8 voltage-gated sodium channels in peripheral nerves,
intercepting pain signals before they reach the brain — with no opioid-related dependency risk. - Two Phase 3 randomized controlled trials (2,000+ patients) confirmed statistically significant pain relief vs. placebo,
with nausea/vomiting rates of 20% vs. 33% for opioids. - A March 2026 Phase 4 trial in aesthetic and reconstructive surgery showed
90.9% of patients required zero opioids throughout recovery — vs. under 10% with conventional multimodal therapy. - JOURNAVX is not yet approved outside the U.S.
Its global rollout, including potential regulatory review in Japan and other markets, remains to be confirmed.
“I want the procedure, but I’m terrified of the pain afterward.”
It’s one of the most common reasons patients hesitate before aesthetic surgery.
For decades, surgeons faced an uncomfortable binary: NSAIDs that weren’t strong enough,
or opioids that carried serious risks of dependency, nausea, and delayed recovery.
In January 2025, the U.S. Food and Drug Administration approved a drug that changes that calculus.
JOURNAVX (suzetrigine), developed by Vertex Pharmaceuticals,
is the first analgesic with a genuinely new mechanism of action approved for acute pain in approximately 25 years.
And in March 2026, Phase 4 data from aesthetic and reconstructive surgery confirmed what early trials suggested:
90.9% of patients recovered without needing a single opioid.
INDEX
Twenty-Five Years Without a New Option
Post-surgical pain is one of medicine’s most persistent unsolved problems.
More than 80% of surgical patients experience moderate-to-severe acute pain after their procedures
(JOURNAVX Patient Brochure, Vertex Pharmaceuticals, 2025).
Until now, the options were essentially two:
The Traditional Two-Option Structure for Post-Surgical Pain
NSAIDs & Acetaminophen (Non-opioid)
Ibuprofen, naproxen, acetaminophen — effective for mild-to-moderate pain.
Often insufficient for the moderate-to-severe acute pain that follows major aesthetic procedures.
Opioid Analgesics
Hydrocodone, oxycodone, morphine — powerful, but carrying well-documented risks:
dependency, nausea, respiratory depression, and delayed recovery.
The third option — effective, non-addictive, and mechanistically distinct — did not exist for roughly 25 years.
The stakes are particularly high in the United States, where the opioid crisis has become a defining public health emergency.
The CDC reports that more than 645,000 people died from opioid overdose over the past two decades (CDC, 2024).
Surgical patients are estimated to be 4 times more likely to develop opioid dependency
than non-surgical patients — placing aesthetic surgeons at the center of a difficult ethical tension.
645,000+
U.S. opioid overdose deaths
over the past 20 years
Source: CDC, 2024
80%+
Surgical patients experiencing
moderate-to-severe acute pain
Source: JOURNAVX Patient Brochure
~25years
Since FDA approved a new-mechanism
acute pain analgesic
Source: Vertex Pharmaceuticals, 2025
How JOURNAVX Works: Closing the NaV1.8 “Pain Gate”
The reason JOURNAVX represents a genuine breakthrough lies in where it acts — not just how strongly.
When tissue is damaged — by surgery, injury, or a laser — peripheral nociceptors generate electrical pain signals.
Those signals travel along nerve fibers to the spinal cord and then to the brain,
where they are finally perceived as pain.
Traditional opioids act on the central nervous system (brain and spinal cord),
dulling the perception of pain — but also triggering euphoria, respiratory depression, and dependency.
JOURNAVX takes a fundamentally different route.
📌 What Is NaV1.8?
- A voltage-gated sodium channel (VGSC) — one of nine subtypes (NaV1.1–NaV1.9)
- Expressed specifically in peripheral pain-sensing neurons (nociceptors),
particularly in dorsal root ganglion (DRG) neurons - Responsible for generating the action potentials that transmit pain signals
- NaV1.8 is peripheral-specific — it is not expressed in the brain or central nervous system
- Suzetrigine’s selectivity for NaV1.8 is more than 31,000-fold greater than for other NaV subtypes
Source: Osteen JD et al. Pain Ther. 2025; PMC12843740
By selectively blocking NaV1.8 in peripheral nerves,
JOURNAVX intercepts pain signals before they ever reach the brain.
Because it does not act centrally, the opioid-associated risks — euphoria, dependency, respiratory depression — do not arise.
This is not a matter of degree. It is a difference in mechanism.
▼ Mechanism Comparison
❌ Opioid Analgesics
- Site of action: Brain & spinal cord (central)
- Dependency risk: High
- Nausea/vomiting: Common (33%)
- Respiratory depression: Present
- Recovery impact: May delay
✅ JOURNAVX (Suzetrigine)
- Site of action: Peripheral nerves (NaV1.8)
- Dependency risk: None observed in trials
- Nausea/vomiting: Lower (20%)
- Respiratory depression: None
- Recovery impact: Does not impair
Source: JOURNAVX Prescribing Information 01/2026; FDA Clinical Trials Data (Trial 1: Abdominoplasty)
Phase 3 Trial Data: 2,000+ Patients, Two Surgical Models
JOURNAVX’s FDA approval rested on two large-scale Phase 3 randomized controlled trials
conducted in aesthetic and orthopedic surgery populations:
abdominoplasty (tummy tuck) and bunionectomy (hallux valgus correction).
Both trials used a 48-hour double-blind, placebo-controlled design.
The primary endpoint was SPID48 — the Sum of Pain Intensity Difference over 48 hours,
a time-weighted measure where higher scores indicate greater sustained pain relief.
📊 Phase 3 Trial Primary Endpoint Results (SPID48)
SPID48 = Sum of Pain Intensity Difference over 48 hours.
Higher scores indicate greater cumulative pain relief over the 48-hour period.
Trial 1: Post-Abdominoplasty
n=447
Trial 2: Post-Bunionectomy
n=426
Note: Higher SPID48 scores indicate greater cumulative pain relief over 48 hours.
Source: Bertoch T et al. Anesthesiology. 2025. doi:10.1097/ALN.0000000000005460; FDA Prescribing Information 01/2026
Critically, JOURNAVX was also compared against opioids (hydrocodone/acetaminophen).
In the abdominoplasty trial, the difference was not statistically significant — meaning JOURNAVX delivered comparable pain relief without opioid risk.
In practical terms: opioid-level analgesia, without opioids.
Pain Score Reduction at 48 Hours — Abdominoplasty (Trial 1)
47% reduction
43% reduction
31% reduction
Note: JOURNAVX was not statistically superior to opioid (hydrocodone/APAP) — it was non-inferior.
It was statistically superior to placebo.
Source: JOURNAVX Patient Brochure; FDA Prescribing Information 01/2026
Phase 4 Aesthetic Surgery Data: March 2026
The most compelling evidence for aesthetic medicine practitioners came in March 2026.
On March 5, 2026, Vertex Pharmaceuticals presented new Phase 4 (post-marketing) data
at the American Academy of Pain Medicine (AAPM) PainConnect 2026 conference in Salt Lake City, Utah.
The study enrolled 99 patients undergoing aesthetic and reconstructive procedures,
including breast reconstruction, cosmetic breast surgery, liposuction, abdominoplasty with liposuction,
and septoplasty.
JOURNAVX was administered as part of a multimodal analgesic regimen
(combined with acetaminophen and ibuprofen) before and after surgery.
🔬 Phase 4 Trial — Aesthetic & Reconstructive Surgery: Key Results
- 90.9% of patients required zero opioids throughout the entire treatment period (up to 14 days)
- 90.7% of patients rated the JOURNAVX-based multimodal regimen as “excellent, very good, or good”
- Among the 9 patients who did use rescue opioids,
the average use was just 2 tablets over 2 days - Zero serious adverse events were reported;
all adverse events were mild-to-moderate - Benchmark comparison: conventional multimodal therapy without JOURNAVX achieved opioid-free recovery in fewer than 10% of patients
Source: Vertex Pharmaceuticals Press Release, March 5, 2026; AAPM PainConnect 2026
Lead author: Samuel Lin, M.D., F.A.C.S., Associate Professor of Surgery, Harvard Medical School
Lead author Dr. Samuel Lin of Harvard Medical School commented that the data
“demonstrate the potential to effectively manage pain while reducing the risks associated with opioid use”
when JOURNAVX is incorporated into post-surgical care.
The implications are significant.
The long-held assumption that opioids are inevitable after aesthetic surgery
may no longer hold.
If more than 90% of patients can recover without them,
the entire risk profile of aesthetic procedures — dependency, nausea, delayed healing — shifts fundamentally.
What This Means for Aesthetic Medicine Globally
JOURNAVX is currently approved only in the United States.
Its availability in other markets — including Japan, the EU, and Asia-Pacific — remains subject to separate regulatory review.
That said, the drug’s implications for the global aesthetic medicine industry are worth examining now.
Patient Experience Transformation
“Fear of post-procedure pain” is one of the most cited reasons patients delay or avoid aesthetic surgery.
A credible opioid-free pain management option could meaningfully reduce that barrier.
Clinic Differentiation
Practices that can offer evidence-based, opioid-free pain protocols
may gain a meaningful competitive advantage in patient acquisition and trust.
Regulatory Pipeline to Watch
FDA approval typically precedes international regulatory submissions by several years.
Whether Vertex has filed or plans to file in Japan, the EU, or other markets is not yet publicly confirmed.
Important Cautions
Outside the U.S., use of JOURNAVX involves significant regulatory and legal considerations.
Known drug interactions include CYP3A inhibitors (e.g., certain antifungals, macrolide antibiotics).
It is contraindicated in patients with severe hepatic impairment.
Current trial data covers only short-term use (up to 14 days).
Dr. Rena
I personally took JOURNAVX (suzetrigine) before undergoing a Sylfirm X treatment at 4mm depth — a procedure that typically causes significant pain — without any topical anesthetic.
My own experience was a dramatic reduction in pain, and I was genuinely surprised by the effect.
As a non-opioid analgesic with a novel mechanism, I believe it has the potential to be a game-changer for patients who have been hesitant to pursue treatment due to pain concerns.
That said, reduced pain sensation also means patients may be less aware of abnormal heat or potential burns during energy-based treatments.
This makes careful patient selection, appropriate device settings, and rigorous intra- and post-procedure safety monitoring more critical than ever.
At our clinic, patient safety remains the top priority, and we are implementing thorough protocols before introducing this to appropriate cases.
What makes JOURNAVX genuinely significant is its selectivity for NaV1.8.
Because it does not act on the brain, it avoids the root mechanism of opioid dependency — not merely its severity.
This is not a marginal improvement. It is a mechanistic departure.
That said, current trial data covers only 48 hours to 14 days of use.
Long-term applications and chronic pain indications remain to be studied.
“Fear of post-procedure pain” is one of the most powerful deterrents in aesthetic medicine.
If JOURNAVX reaches global markets, it won’t just change pain management —
it will change who chooses to have surgery in the first place.
Summary
- JOURNAVX (suzetrigine) received FDA approval in January 2025 —
the first new-mechanism analgesic for acute pain in approximately 25 years.
It selectively blocks NaV1.8 sodium channels in peripheral nerves,
stopping pain signals before they reach the brain. - Two Phase 3 RCTs (2,000+ patients) demonstrated statistically significant pain relief vs. placebo,
with non-inferior efficacy compared to opioids and a lower rate of nausea/vomiting (20% vs. 33%). - Phase 4 data from aesthetic and reconstructive surgery (March 2026) showed
90.9% of patients achieved opioid-free recovery —
compared to fewer than 10% with conventional multimodal therapy alone. - JOURNAVX is currently approved only in the United States.
Use outside the U.S. involves regulatory and legal considerations;
international approval timelines have not been publicly confirmed by Vertex.
Because NaV1.8 is not expressed in the brain or central nervous system,
the mechanism that drives opioid-induced euphoria and dependency does not apply.
However, long-term use data (beyond 14 days) have not yet been collected,
and further research is needed to characterize any chronic-use risk profile.
Source: JOURNAVX Prescribing Information 01/2026; PMC12676188
Some physicians have used it off-label for energy-based aesthetic treatments
(e.g., administering 100mg approximately 3–5 hours before a procedure),
but this is not a manufacturer-recommended indication.
Its efficacy for chronic pain has not been studied,
and use beyond 14 days has not been evaluated in clinical trials.
Source: FDA Prescribing Information; JOURNAVX internal reference materials (July 2026)
In markets such as Japan, the EU, and other Asia-Pacific countries,
the drug has not been approved by local regulatory authorities.
Use in those markets would require individual physician-initiated import procedures
and carries significant regulatory and legal implications.
Vertex Pharmaceuticals has not publicly confirmed international regulatory filing plans.
Source: JOURNAVX internal reference materials, “Note: Not approved in Japan” (July 2026)
Sources:
1. Vertex Pharmaceuticals. FDA Approves JOURNAVX (suzetrigine). Press Release, January 30, 2025. news.vrtx.com
2. JOURNAVX (suzetrigine) tablets. Full Prescribing Information. Vertex Pharmaceuticals Incorporated. Revised 01/2026.
3. Bertoch T, D’Aunno D, McCoun J, et al. Suzetrigine, a non-opioid NaV1.8 inhibitor for treatment of moderate-to-severe acute pain: two phase 3 randomized clinical trials. Anesthesiology. 2025. doi:10.1097/ALN.0000000000005460
4. Osteen JD, Immani S, Tapley TL, et al. Pharmacology and mechanism of action of suzetrigine, a potent and selective NaV1.8 pain signal inhibitor. Pain Ther. Published online January 8, 2025. doi:10.1007/s40122-024-00697-0
5. Rejeev MM, Pavithran K, Palatty P. Clinical Efficacy and Safety Profile of Suzetrigine. Cureus. 2025;17(11):e96054. doi:10.7759/cureus.96054 PMC12676188
6. PMC12843740. Suzetrigine, a NaV1.8 Inhibitor as a Novel Approach for Pain Therapy. PMC. 2025.
7. Vertex Pharmaceuticals. “Vertex to Present New Data on JOURNAVX Following Aesthetic and Reconstructive Procedures.” Press Release, March 5, 2026. AAPM PainConnect 2026.
8. CDC. Opioid Overdose Data. 2024. cdc.gov
9. JOURNAVX Patient Brochure. “Where Pain Starts, JOURNAVX Begins.” Vertex Pharmaceuticals, 2025.
Disclaimer: This article is produced by the NERO DOCTOR/BEAUTY editorial team based on publicly available primary sources. JOURNAVX is not approved outside the United States as of publication. This article does not constitute medical advice or a recommendation for any specific treatment or product. All clinical decisions should be made in accordance with current medical evidence and applicable regulations.
